Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Amar Karalli"'
Autor:
Charlotte Ebeling Barbier, Ulf Bondesson, Rickard Nyman, Frans Duraj, Torkel B. Brismar, Hans Lennernäs, Agneta Norén, Rimma Axelsson, Elsa Lilienberg, Per Stål, Ilse R. Dubbelboer, Erik Sjögren, Amar Karalli, Mikael Hedeland
Publikováno v:
Molecular Pharmaceutics. 15:336-340
Reply to "Comment on 'In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma'"
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7945ea239467bad00f7f373a1749ea6b
https://doi.org/10.1021/acs.molpharmaceut.7b00840
https://doi.org/10.1021/acs.molpharmaceut.7b00840
Autor:
Rimma Axelsson, Per Stål, Torkel B. Brismar, Staffan Wahlin, Mojgan Haji, Johan Teiler, Amar Karalli, Elin Seth
Publikováno v:
Scandinavian journal of gastroenterology. 54(7)
Aim: Doxorubicin-eluting beads transarterial chemoembolization (DEB-TACE) is reported to improve survival and tolerability when compared with conventional lipiodol-TACE (cTACE) for the treatment of hepatocellular carcinoma (HCC). The aim of this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::490cd4d8b1422fcbced6b6b910a9f2bf
https://pubmed.ncbi.nlm.nih.gov/31287338
https://pubmed.ncbi.nlm.nih.gov/31287338
Autor:
Torkel B. Brismar, Bela Bozoki, Lars Lundell, Amar Karalli, Rimma Axelsson, Ramin Ghaffarpour, Ove Gustafsson
Publikováno v:
Journal of vascular and interventional radiology : JVIR. 28(12)
Purpose To prospectively assess feasibility, safety, and cytoreductive effect of transarterial chemoembolization on renal cell carcinoma (RCC) using drug-eluting embolic agent (DEE) saturated with doxorubicin compared with transarterial embolization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93b02a63c746b636a23887b9009e5bef
https://pubmed.ncbi.nlm.nih.gov/28947365
https://pubmed.ncbi.nlm.nih.gov/28947365
Autor:
Elsa Lilienberg, Per Stål, Agneta Norén, Mikael Hedeland, Torkel B. Brismar, Erik Sjögren, Rickard Nyman, Frans Duraj, Hans Lennernäs, Amar Karalli, Ilse R. Dubbelboer, Charlotte Ebeling Barbier, Rimma Axelsson, Ulf Bondesson
Publikováno v:
Molecular pharmaceutics. 14(2)
Doxorubicin (DOX) delivered in a lipiodol-based emulsion (LIPDOX) or in drug-eluting beads (DEBDOX) is used as palliative treatment in patients with intermediate-stage hepatocellular carcinoma (HCC). The primary objective of this study was to evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fddabb53b3d2a7eb4cf7604c24107b6f
https://pubmed.ncbi.nlm.nih.gov/29193977
https://pubmed.ncbi.nlm.nih.gov/29193977
Autor:
Amar Karalli, Thomas Henzler, Michael A. Fischer, Holger Haubenreisser, Rishi P. Mathew, Herman P. Marquez, Hatem Alkadhi, Torkel B. Brismar
Publikováno v:
European journal of radiology. 91
To prospectively monitor changes in tumor perfusion of hepatocellular carcinoma (HCC) in response to doxorubicin-eluted bead based transarterial chemoembolization (DEB-TACE) using perfusion-CT (P-CT).24 patients (54-79 years) undergoing P-CT before a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2742a37093e51e04b24d6c112c864f11
https://pubmed.ncbi.nlm.nih.gov/28629564
https://pubmed.ncbi.nlm.nih.gov/28629564